Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.56 |
| ▸ | CHKA | P35790 | 13/20 | 0.56 |
| ▸ | BCHE | P06276 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262350 | 0.88 | CHKA (0.48) | CHKABCHEACHE | |
| SCHEMBL262351 | 0.88 | CHKA (0.48) | CHKABCHEACHE | |
| Hydrochloric Acid SCHEMBL9674296 | 0.82 | USP2 (0.43) | CHKABCHEACHE | |
| SCHEMBL9834829 | 0.80 | USP2 (0.44) | CHKABCHEACHE | |
| SCHEMBL9329679 | 0.78 | CHKA (0.62) | CHKABCHEACHE | |
| Hydrochloric Acid SCHEMBL9328059 | 0.78 | CHKA (0.59) | CHKABCHEACHE | |
| Bromide SCHEMBL9327388 | 0.77 | CHKA (0.66) | CHKABCHEACHE | |
| SCHEMBL9328178 | 0.76 | CHKA (0.61) | CHKABCHEACHE | |
| Bromide SCHEMBL9327138 | 0.74 | CHKA (0.65) | CHKABCHEACHE | |
| SCHEMBL15212015 | 0.74 | CHKA (0.59) | CHKABCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268237-B2 | Direct dianhydride synthesis | GENERAL ELECTRIC COMPANY (US) | 2007-09-11 | — | — | US | claimed |
| US-20060205958-A1 | Direct dianhydride synthesis | GENERAL ELECTRIC COMPANY | 2006-09-14 | — | — | US | claimed |
| EP-2280963-B1 | METHOD OF PURIFYING DIANHYDRIDES, THE DIANHYDRIDES FORMED THEREBY, AND POLYETHERIMIDES FORMED THEREFROM | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2016-07-20 | — | — | EP | disclosed |
| CN-105218496-A | The method of purifying dianhydride | SABIC FOUNDATIONAL GLOBAL TECHNOLOGY CO LTD | 2016-01-06 | — | — | CN | disclosed |
| EP-2097375-B1 | METHOD FOR PURIFYING BISIMIDES | SABIC INNOVATIVE PLASTICS IP (NL) | 2013-04-24 | — | — | EP | disclosed |
| EP-2089348-B1 | METHOD FOR MAKING POLYETHERIMIDES | SABIC INNOVATIVE PLASTICS IP (NL) | 2013-02-20 | — | — | EP | disclosed |
| US-8134016-B2 | Method for purifying dianhydrides | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2012-03-13 | — | — | US | disclosed |
| US-8013173-B2 | Method of purifying dianhydrides, the dianhydrides formed thereby, and polyetherimides formed therefrom | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2011-09-06 | — | — | US | disclosed |
| EP-2094691-B1 | METHOD FOR PURIFYING DIANHYDRIDES | SABIC INNOVATIVE PLASTICS IP (NL) | 2011-05-25 | — | — | EP | disclosed |
| EP-2280963-A1 | METHOD OF PURIFYING DIANHYDRIDES, THE DIANHYDRIDES FORMED THEREBY, AND POLYETHERIMIDES FORMED THEREFROM | SABIC Innovative Plastics IP B.V. (NL) | 2011-02-09 | — | — | EP | disclosed |
| US-20090247727-A1 | Method of Purifying Dianhydrides, the Dianhydrides Formed Thereby, and Polyetherimides Formed Therefrom | SHPP GLOBAL TECHNOLOGIES B.V. (NL) | 2009-10-01 | — | — | US | disclosed |
| WO-2008063208-A1 | METHOD FOR PURIFYING BISIMIDES | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063206-A1 | METHOD FOR MAKING POLYETHERIMIDES | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063207-A1 | METHOD FOR PURIFYING DIANHYDRIDES | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2008-05-29 | — | — | WO | disclosed |
| US-7268237-B2 | Direct dianhydride synthesis | GENERAL ELECTRIC COMPANY (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070073066-A1 | Method for purifying dianhydrides | GENERAL ELECTRIC COMPANY (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070073063-A1 | Method for purifying bisimides | GENERAL ELECTRIC COMPANY (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070073035-A1 | Method for making polyetherimides | GENERAL ELECTRIC COMPANY (US) | 2007-03-29 | — | — | US | disclosed |
| US-20060293528-A1 | Method of purifying dianhydrides | GENERAL ELECTRIC COMPANY | 2006-12-28 | — | — | US | disclosed |
| US-20060205958-A1 | Direct dianhydride synthesis | GENERAL ELECTRIC COMPANY | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205958-A1 | Direct dianhydride synthesis | HDHD5, DOHH, DBH | ACHE 1387/4885CHKA 3705/4885BCHE 683/4885 |
| US-20070073063-A1 | Method for purifying bisimides | FHIT, PBRM1, TNS4 | ACHE 3216/4885CHKA 4501/4885BCHE 1284/4885 |
| US-20060293528-A1 | Method of purifying dianhydrides | CA3, UROD, CA7 | ACHE 2507/4885CHKA 4432/4885BCHE 959/4885 |
| US-20070073066-A1 | Method for purifying dianhydrides | AQP4, TRRAP, GYPA | ACHE 3414/4885CHKA 4567/4885BCHE 2510/4885 |
| US-20090247727-A1 | Method of Purifying Dianhydrides, the Dianhydrides Formed Thereby, and Polyetherimides Formed Therefrom | CA7, CA4, CA13 | ACHE 3011/4885CHKA 4367/4885BCHE 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.